In this context, post-mortem analysis of brain tissue from both MS patients and EAE mouse/rat models elicited potential therapeutic targets through: (1) blockade of P2X7 receptor and stimulation of A1 receptor, inhibiting inflammation; (2) P2Y12 receptor stimulation, favoring remyelination; and (3) blockade of A2B receptors and CD73, inhibiting the infiltration of leukocytes into the CNS. Here, P2RX7 is linked to myeloid sarcoma.